Skip to navigation menu Skip to main content Skip to footer

Our Grantees

A person wearing a lab coat and gloves holds a flask with pink liquid, using a pipette. The scene is set in a laboratory with more flasks and green test tube racks in the background.
Smiling woman with medium-length brown hair, wearing round black glasses, a beige blazer, and a white turtleneck, posed against a plain light background.
Gunda Georg, PhD Regents Professor and Department Head

$342,000 – Awarded January 2021

$150,000 – Awarded April 2018

University of Minnesota College of Pharmacy
Minneapolis, MN

About

​Dr. Gunda Georg is a Regents Professor, Department Head, and Endowed Chair at the University of Minnesota. She is also the co-Editor-In-Chief of the Journal of Medicinal Chemistry. Her group has published over 200 scientific articles on the design, synthesis, and evaluation of biologically active agents. In addition to male contraception, her lab investigates areas of cancer and female contraception.

Our Grant

With MCI’s support, Gunda’s lab is investigating multiple avenues of male contraception. One is the testis-specific serine kinase (TSSK) family, where she is looking for inhibitors of TSSK1 and TSSK2. These proteins are expressed post-meiotically, and are likely involved in multiple steps that could make them excellent contraceptive targets. ​The other target, Na, K ATPase is involved in sperm motility, and could potentially be targeted for either male or female contraception. MCI’s support for Dr. Georg’s work comes in the form of grants as well as a program-related investment.

With their focus on translational research, Gunda and her lab are focused on developing these targets for contraception, and moving them towards the clinical side. Recently, Dr. Georg said, “Reversible, effective male birth control is within sight. World Health Organization numbers suggest that reducing sperm motility by 50 percent or less is sufficient to temporarily make a man infertile. Our ongoing research brings us one step closer to expanding the options for male birth control, providing the world’s 7.6 billion people with a much-needed option for safe and reversible contraception.”

Smiling woman with medium-length brown hair, wearing round black glasses, a beige blazer, and a white turtleneck, posed against a plain light background.
Gunda Georg, PhD Regents Professor and Department Head

$342,000 – Awarded January 2021

$150,000 – Awarded April 2018

University of Minnesota College of Pharmacy
Minneapolis, MN

About

​Dr. Gunda Georg is a Regents Professor, Department Head, and Endowed Chair at the University of Minnesota. She is also the co-Editor-In-Chief of the Journal of Medicinal Chemistry. Her group has published over 200 scientific articles on the design, synthesis, and evaluation of biologically active agents. In addition to male contraception, her lab investigates areas of cancer and female contraception.

Our Grant

With MCI’s support, Gunda’s lab is investigating multiple avenues of male contraception. One is the testis-specific serine kinase (TSSK) family, where she is looking for inhibitors of TSSK1 and TSSK2. These proteins are expressed post-meiotically, and are likely involved in multiple steps that could make them excellent contraceptive targets. ​The other target, Na, K ATPase is involved in sperm motility, and could potentially be targeted for either male or female contraception. MCI’s support for Dr. Georg’s work comes in the form of grants as well as a program-related investment.

With their focus on translational research, Gunda and her lab are focused on developing these targets for contraception, and moving them towards the clinical side. Recently, Dr. Georg said, “Reversible, effective male birth control is within sight. World Health Organization numbers suggest that reducing sperm motility by 50 percent or less is sufficient to temporarily make a man infertile. Our ongoing research brings us one step closer to expanding the options for male birth control, providing the world’s 7.6 billion people with a much-needed option for safe and reversible contraception.”

A non-hormonal pill could soon expand men’s birth control options
MCI Grantee: University of Minnesota (Dr. Gunda Georg)

Publications

Physiological Characterization of the Transporter-Mediated Uptake of the Reversible Male Contraceptive H2-Gamendazole Across the Blood-Testis Barrier. Raymond K. Hau, Joseph S. Tash, Gunda Ingrid Georg, Stephen H. Wright and Nathan J. Cherrington Journal of Pharmacology and Experimental Therapeutics July 2, 2022, JPET-AR-2022-001195; DOI: https://doi.org/10.1124/jpet.122.001195

Noman, M., Kyzer, J. L., Chung, S., Wolgemuth, D. J., & Georg, G. I. (2020). Retinoic acid receptor antagonists for male contraception: current status†. Biology of reproduction, 103(2), 390–399. https://doi.org/10.1093/biolre/ioaa122

Hawkinson, Jon E., Rondedrick Sinville, Deepti Mudaliar, Jagathpala Shetty, Timothy Ward, John C. Herr, and Gunda I. Georg. “Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).” ChemMedChem 12, no. 22 (November 22, 2017): 1857–65. https://doi.org/10.1002/cmdc.201700503.

Shetty, Jagathpala, Rondedrick Sinville, Igor A. Shumilin, Wladek Minor, Jianhai Zhang, Jon E. Hawkinson, Gunda I. Georg, Charles J. Flickinger, and John C. Herr. “Recombinant Production of Enzymatically Active Male Contraceptive Drug Target HTSSK2 – Localization of the TSKS Domain Phosphorylated by TSSK2.” Protein Expression and Purification 121 (May 2016): 88–96. https://doi.org/10.1016/j.pep.2016.01.009.

Li, Y., J. Sosnik, L. Brassard, M. Reese, N. A. Spiridonov, T. C. Bates, G. R. Johnson, J. Anguita, P. E. Visconti, and A. M. Salicioni. “Expression and Localization of Five Members of the Testis-Specific Serine Kinase (Tssk) Family in Mouse and Human Sperm and Testis.” Molecular Human Reproduction 17, no. 1 (January 1, 2011): 42–56. https://doi.org/10.1093/molehr/gaq071.

Syeda, S. S., Sánchez, G., McDermott, J. P., Hong, K. H., Blanco, G., & Georg, G. I. (2020). The Na+ and K+ transport system of sperm (ATP1A4) is essential for male fertility and an attractive target for male contraception†. Biology of Reproduction, 103(2), 343–356. https://doi.org/10.1093/biolre/ioaa093